Table 4.
Univariate logistic regression analysis. The highlighted variables are significantly associated with higher odds of death.
| Death Odds ratio | IC 95% | |||
|---|---|---|---|---|
| Generals | Age (> 65) | 1.680 | 0.601 | 4.697 |
| Time between symptoms and itolizumab (> 7) | 5.625 | 1.862 | 16.989 | |
| Neurological symptoms | 4.778 | 1.076 | 21.224 | |
| Comorbidities | Hypertension | 0.613 | 0.220 | 1.709 |
| Diabetes Mellitus | 2.024 | 0.712 | 5.753 | |
| Cardiovascular disease | 1.813 | 0.644 | 5.102 | |
| COPD | 0.952 | 0.216 | 4.197 | |
| Cancer | 2.000 | 0.264 | 15.163 | |
| Chronic renal disease | 4.778 | 1.076 | 21.224 | |
| Asthma | 1.583 | 0.478 | 5.246 | |
| Obesity | 1.500 | 0.307 | 7.326 | |
| Nutrition deficit | 0.327 | 0.066 | 1.634 | |
| Baseline lab biomarkers | AST (> 22.1 IU L−1) | 10.500 | 2.462 | 44.78 |
| D‐dimer (> 1.35 µg mL−1) | 6.857 | 1.124 | 41.827 | |
| ALC (> 7.60 × 109 L−1) | 4.978 | 1.610 | 15.387 | |
| Neutrophils (> 5.57 × 109 L−1) | 8.196 | 2.311 | 29.073 | |
| NLR (> 8.85) | 26.444 | 5.788 | 120.819 | |
| PLR (> 146.2) | 6.500 | 1.594 | 26.511 | |
| IL‐6 (> 53.4 pg mL−1) | 7.083 | 1.075 | 46.478 | |
The highlighted variables are significantly associated with higher odds of death.